274 related articles for article (PubMed ID: 26187510)
1. (90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies.
Picozzi VJ; Ramanathan RK; Lowery MA; Ocean AJ; Mitchel EP; O'Neil BH; Guarino MJ; Conkling PR; Cohen SJ; Bahary N; Frank RC; Dragovich T; Bridges BB; Braiteh FS; Starodub AN; Lee FC; Gribbin TE; Richards DA; Lee M; Korn RL; Pandit-Taskar N; Goldsmith SJ; Intenzo CM; Sheikh A; Manzone TC; Horne H; Sharkey RM; Wegener WA; O'Reilly EM; Goldenberg DM; Von Hoff DD
Eur J Cancer; 2015 Sep; 51(14):1857-64. PubMed ID: 26187510
[TBL] [Abstract][Full Text] [Related]
2. Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial.
Ocean AJ; Pennington KL; Guarino MJ; Sheikh A; Bekaii-Saab T; Serafini AN; Lee D; Sung MW; Gulec SA; Goldsmith SJ; Manzone T; Holt M; O'Neil BH; Hall N; Montero AJ; Kauh J; Gold DV; Horne H; Wegener WA; Goldenberg DM
Cancer; 2012 Nov; 118(22):5497-506. PubMed ID: 22569804
[TBL] [Abstract][Full Text] [Related]
3. A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial.
Fuchs CS; Azevedo S; Okusaka T; Van Laethem JL; Lipton LR; Riess H; Szczylik C; Moore MJ; Peeters M; Bodoky G; Ikeda M; Melichar B; Nemecek R; Ohkawa S; Świeboda-Sadlej A; Tjulandin SA; Van Cutsem E; Loberg R; Haddad V; Gansert JL; Bach BA; Carrato A
Ann Oncol; 2015 May; 26(5):921-927. PubMed ID: 25609246
[TBL] [Abstract][Full Text] [Related]
4. Pretargeted radioimmunotherapy of pancreatic cancer xenografts: TF10-90Y-IMP-288 alone and combined with gemcitabine.
Karacay H; Sharkey RM; Gold DV; Ragland DR; McBride WJ; Rossi EA; Chang CH; Goldenberg DM
J Nucl Med; 2009 Dec; 50(12):2008-16. PubMed ID: 19949026
[TBL] [Abstract][Full Text] [Related]
5. Low-dose radioimmunotherapy ((90)Y-PAM4) combined with gemcitabine for the treatment of experimental pancreatic cancer.
Gold DV; Schutsky K; Modrak D; Cardillo TM
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3929S-37S. PubMed ID: 14506191
[TBL] [Abstract][Full Text] [Related]
6. Treatment of advanced pancreatic carcinoma with 90Y-Clivatuzumab Tetraxetan: a phase I single-dose escalation trial.
Gulec SA; Cohen SJ; Pennington KL; Zuckier LS; Hauke RJ; Horne H; Wegener WA; Teoh N; Gold DV; Sharkey RM; Goldenberg DM
Clin Cancer Res; 2011 Jun; 17(12):4091-100. PubMed ID: 21527562
[TBL] [Abstract][Full Text] [Related]
7. Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): study protocol for a multicentre randomized controlled trial.
Versteijne E; van Eijck CH; Punt CJ; Suker M; Zwinderman AH; Dohmen MA; Groothuis KB; Busch OR; Besselink MG; de Hingh IH; Ten Tije AJ; Patijn GA; Bonsing BA; de Vos-Geelen J; Klaase JM; Festen S; Boerma D; Erdmann JI; Molenaar IQ; van der Harst E; van der Kolk MB; Rasch CR; van Tienhoven G;
Trials; 2016 Mar; 17(1):127. PubMed ID: 26955809
[TBL] [Abstract][Full Text] [Related]
8. Combined 90Yttrium-DOTA-labeled PAM4 antibody radioimmunotherapy and gemcitabine radiosensitization for the treatment of a human pancreatic cancer xenograft.
Gold DV; Modrak DE; Schutsky K; Cardillo TM
Int J Cancer; 2004 Apr; 109(4):618-26. PubMed ID: 14991585
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale.
Colucci G; Giuliani F; Gebbia V; Biglietto M; Rabitti P; Uomo G; Cigolari S; Testa A; Maiello E; Lopez M
Cancer; 2002 Feb; 94(4):902-10. PubMed ID: 11920457
[TBL] [Abstract][Full Text] [Related]
10. Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: an AGEO randomised phase II study (FIRGEM).
Trouilloud I; Dupont-Gossard AC; Malka D; Artru P; Gauthier M; Lecomte T; Aparicio T; Thirot-Bidault A; Lobry C; Asnacios A; Manet-Lacombe S; Fein F; Dubreuil O; Landi B; Zaanan A; Bonnetain F; Taïeb J
Eur J Cancer; 2014 Dec; 50(18):3116-24. PubMed ID: 25454414
[TBL] [Abstract][Full Text] [Related]
11. Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer.
Wolpin BM; O'Reilly EM; Ko YJ; Blaszkowsky LS; Rarick M; Rocha-Lima CM; Ritch P; Chan E; Spratlin J; Macarulla T; McWhirter E; Pezet D; Lichinitser M; Roman L; Hartford A; Morrison K; Jackson L; Vincent M; Reyno L; Hidalgo M
Ann Oncol; 2013 Jul; 24(7):1792-1801. PubMed ID: 23448807
[TBL] [Abstract][Full Text] [Related]
12. Consolidation anti-CD22 fractionated radioimmunotherapy with
Kraeber-Bodere F; Pallardy A; Maisonneuve H; Campion L; Moreau A; Soubeyran I; Le Gouill S; Tournilhac O; Daguindau E; Jardel H; Morineau N; Bouabdallah K; Gyan E; Moles MP; Gressin R; Berthou C; Sadot S; Moreau P; Deau B; Bodet-Milin C; Cazeau AL; Garin E; Salaun PY; Vuillez JP; Gouilleux-Gruart V; Barbet J; Wegener WA; Goldenberg DM; Lamy T; Soubeyran P
Lancet Haematol; 2017 Jan; 4(1):e35-e45. PubMed ID: 27964867
[TBL] [Abstract][Full Text] [Related]
13. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group.
Poplin E; Feng Y; Berlin J; Rothenberg ML; Hochster H; Mitchell E; Alberts S; O'Dwyer P; Haller D; Catalano P; Cella D; Benson AB
J Clin Oncol; 2009 Aug; 27(23):3778-85. PubMed ID: 19581537
[TBL] [Abstract][Full Text] [Related]
14. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial.
Goldstein D; El-Maraghi RH; Hammel P; Heinemann V; Kunzmann V; Sastre J; Scheithauer W; Siena S; Tabernero J; Teixeira L; Tortora G; Van Laethem JL; Young R; Penenberg DN; Lu B; Romano A; Von Hoff DD
J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25638248
[TBL] [Abstract][Full Text] [Related]
15. Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma.
Abdel-Wahab R; Varadhachary GR; Bhosale PR; Wang X; Fogelman DR; Shroff RT; Overman MJ; Wolff RA; Javle M
J Hematol Oncol; 2018 May; 11(1):71. PubMed ID: 29843755
[TBL] [Abstract][Full Text] [Related]
16. A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma.
Ko AH; Youssoufian H; Gurtler J; Dicke K; Kayaleh O; Lenz HJ; Keaton M; Katz T; Ballal S; Rowinsky EK
Invest New Drugs; 2012 Aug; 30(4):1597-606. PubMed ID: 21629990
[TBL] [Abstract][Full Text] [Related]
17. Pancreatic proteolytic enzyme therapy compared with gemcitabine-based chemotherapy for the treatment of pancreatic cancer.
Chabot JA; Tsai WY; Fine RL; Chen C; Kumah CK; Antman KA; Grann VR
J Clin Oncol; 2010 Apr; 28(12):2058-63. PubMed ID: 19687327
[TBL] [Abstract][Full Text] [Related]
18. Feasibility and efficacy of combination therapy with preoperative full-dose gemcitabine, concurrent three-dimensional conformal radiation, surgery, and postoperative liver perfusion chemotherapy for T3-pancreatic cancer.
Ohigashi H; Ishikawa O; Eguchi H; Takahashi H; Gotoh K; Yamada T; Yano M; Nakaizumi A; Uehara H; Tomita Y; Nishiyama K
Ann Surg; 2009 Jul; 250(1):88-95. PubMed ID: 19561477
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma.
Tempero M; Plunkett W; Ruiz Van Haperen V; Hainsworth J; Hochster H; Lenzi R; Abbruzzese J
J Clin Oncol; 2003 Sep; 21(18):3402-8. PubMed ID: 12885837
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01).
Uesaka K; Boku N; Fukutomi A; Okamura Y; Konishi M; Matsumoto I; Kaneoka Y; Shimizu Y; Nakamori S; Sakamoto H; Morinaga S; Kainuma O; Imai K; Sata N; Hishinuma S; Ojima H; Yamaguchi R; Hirano S; Sudo T; Ohashi Y;
Lancet; 2016 Jul; 388(10041):248-57. PubMed ID: 27265347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]